Article thumbnail

Clinical Significance of MicroRNA Expression Profiles and Polymorphisms in Lung Cancer Development and Management

By Francesca Megiorni, Antonio Pizzuti and Luigi Frati

Abstract

Lung cancers account for a huge percentage of death in industrialized countries, and hence there is an increasing call for the development of novel treatments. These malignancies are caused by a combination of environmental factors, principally cigarette smoking and genetic alterations. MicroRNAs (miRNAs) are a recently discovered class of regulatory noncoding small RNAs with a significance in numerous biological processes. Strong evidence links miRNA impaired expression profiles and pathways to the etiology of several diseases, including neoplasia. This paper focuses on the emerging role of miRNA function in lung cancer development with particular highlighting on the use of miRNA profiles and polymorphisms for the molecular and biological characterization of tumor pulmonary growth and progression. Furthermore, we underline the potential utility of lung cancer-associated miRNAs as clinical biomarkers with a diagnostic, prognostic, and therapeutic significance and give emphasis to the promising novel miRNA-based curative strategies

Topics: Review Article
Publisher: SAGE-Hindawi Access to Research
OAI identifier: oai:pubmedcentral.nih.gov:3146996
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (2004). A .M .D e n l i ,B .B .T o p s ,R .H .P l a s t e r k ,R .F .K e t t i n g ,a n d
  2. (2009). A functional genetic variant in microRNA-196a2 is associated with increased susceptibility of lung cancer in
  3. (2011). A novel cationic liposome formulation for efficient gene delivery via a pulmonary route,”
  4. (2011). a o ,L .L i u ,X .L u ,a n dY .S h u ,“ C i r c u l a t i n gm i c r o R N A s : possible prediction biomarkers for personalized therapy of non-small-cell lung carcinoma,”
  5. (2005). A polycistronic MicroRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation,”Cancer
  6. (2007). Aberrant allele frequencies of the SNPs located in microRNA target sites are potentially associated with human cancers,”
  7. (2010). Accurate classification of non-small cell lung carcinoma using a novel microRNA-based approach,”
  8. (2010). Adjuvant therapy in non-small cell lung cancer: current and future directions,”
  9. and miR-17-92: small-sized major players in lung cancer development,”
  10. (2010). ang,andL.H uang,“T argetednanoparticles deliver siRNA to melanoma,”
  11. (2011). ang,J .S.Y ang,X.P an,W .De,andL.B .C he n, “MicroRNA-451 functions as a tumor suppressor in human non-small cell lung cancer by targeting ras-related protein 14 (RAB14),” Oncogene,
  12. (2010). assembly pathways,”
  13. (2010). Association of a common AGO1 variant with lung cancer risk: a two-stage case-control study,”
  14. (2007). Cancer statistics,
  15. (2006). Control of translation and mRNA degradation by miRNAs and siRNAs,”
  16. (2010). Deregulated expression of miR-21, miR-143 and miR-181a in non small cell lung cancer is related to clinicopathologic characteristics or patient prognosis,”
  17. (2009). Diagnostic assay based on hsa-miR-205 expression distinguishes squamous from nonsquamous non-small-cell lung carcinoma,”
  18. (2005). e r e z i k o v ,V .G u r y e v ,J .v a nd eB e l t ,E .W i e n h o l d s
  19. (2010). Early detection of lung adenocarcinomainsputumbyapanelofmicroRNAmarkers,”
  20. (2010). EGFR promotes lung tumorigenesis by activating miR-7 through a Ras/ERK/Myc pathway that targets the
  21. (2008). EGFR regulation by microRNA in lung cancer: correlation with clinical response and survival to gefitinib and EGFR expression in cell lines,”
  22. (2007). Epigenetics and microRNAs,”
  23. (2010). Evaluation of microRNA expression profiles that may predict after surgical resection recurrence of localized stage i nonsmall cell lung cancer,”
  24. (2008). Genetic variants of miRNA sequences and non-small cell lung cancer survival,”
  25. (2010). Genetic variation in microRNA networks: the implications for cancer research,”
  26. (2010). Hsa-miR-125a-3p and hsa-miR-125a-5p are downregulated in non-small cell lung cancer and have inverse effects on invasion and migration of lung cancer cells,”
  27. (2004). Human microRNA genes are frequently located at fragile sites and genomic regions involved incancers,”Proceedingsofthe
  28. (2010). Inherited polymorphisms in the RNA-mediated interference machinery affect microRNA expression and lung cancer survival,”
  29. (1993). Interobserver variability in histopathologic subtyping and grading of pulmonary adenocarcinoma,”
  30. (2010). K e n t ,R .R .C h i v u k u l a ,M .M u l l e n d o r ee ta l .
  31. (2010). Kelnar et al., “Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34,”
  32. (2008). L.J.Chin,E.Ratner,S.Lengetal.,“ASNPinalet-7microRNA complementary site in the KRAS 3’UTR increases non-small cell lung cancer risk,”
  33. (2003). M a s s i o na n dD .P .C a r b o n e ,“ T h em o l e c u l a rb a s i s of lung cancer: molecular abnormalities and therapeutic implications,”
  34. (2009). M ishraandJ .R.Bertino ,“M icr oRN Apolymorphisms:the future of pharmacogenomics, molecular epidemiology and individualized medicine,”
  35. (2010). M.S.Nicoloso,H.Sun,R.Spizzoetal.,“Single-nucleotidepolymorphisms inside microRNA target sites influence tumor
  36. (2008). M.Wu,N.Jolicoeur,Z.Lietal.,“GeneticvariationsofmicroRNAs in human cancer and their effects on the expression of miRNAs,”
  37. (2010). MicroRNA 92a2∗:abiomarkerpredictiveforchemoresistanceandprognostic for survival in patients with small cell lung cancer,”
  38. (2005). MicroRNA biogenesis: coordinated cropping and dicing,”
  39. (2010). MicroRNA expression differentiates histology and predicts survival of lung cancer,”
  40. (2005). MicroRNA expression profiles classify human cancers,”
  41. (2008). MicroRNA signature predicts survival and relapse in lung cancer,”
  42. (2011). MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer,”
  43. MicroRNA-328 is associated with (non-small) cell lung cancer (NSCLC) brain metastasis and mediates NSCLC migration,”
  44. (2011). MicroRNA-related genetic variants as predictors of early stage non–small cell lung cancer clinical outcomes,”
  45. (2008). MicroRNA: an emerging therapeutictargetandinterventiontool,”InternationalJournal of Molecular Sciences,
  46. (2007). MicroRNAs as oncogenes and tumor suppressors,”
  47. (2007). MicroRNAs as potential agents to alter resistance to cytotoxic anticancer therapy,”
  48. (2004). MicroRNAs: genomics, biogenesis, mechanism, and function,”
  49. (2010). MicroRNAs: predictors and modifiers of chemo- and radiotherapy in different tumour types,”
  50. (2011). MiR-145 inhibits cell proliferation of human lung adenocarcinoma by targeting
  51. MiR126 restoration down-regulate VEGF and inhibit the growth of lung cancer cell lines in vitro and in vivo,”
  52. (2008). miRBase: tools for microRNA genomics,”
  53. (2010). miRNA-145 inhibits nonsmall cell lung cancer cell proliferation by targeting c-Myc,”
  54. (2010). Modulation of K-Ras-dependent lung tumorigenesis by
  55. (2010). Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy,”
  56. (2011). Nucleobase and ribose modifications control immunostimulation by a MicroRNA-122-mimetic RNA,”
  57. (2009). O’Donnell et al., “Therapeutic microRNAdeliverysuppressestumorigenesisinamurineliver cancer model,”
  58. (1970). Observer variability in the histopathologic diagnosis of lung cancer,”
  59. (2010). Ouyang et al., “MicroRNA-31 functions as an oncogenic microRNA in mouse and human lung cancer cells by repressing specific tumor suppressors,”
  60. (2011). Plasma microRNAs as potential biomarkers for non-small-cell lung cancer,”
  61. (2009). Potent inhibition of microRNA in vivo without degradation,”
  62. (2011). Prognostic implications of miR-16 expression levels in resected non-small-cell lung cancer,”
  63. (2007). Progress in the epidemiological understanding of gene-environment interactions in major diseases:
  64. (2010). Regression of murine lung tumors by the let-7 microRNA,”
  65. (2010). Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer,”
  66. (2011). Shamburek,andA.T .R emaley ,“MicroRN Asaretransportedinplasma and delivered to recipient cells by high-density lipoproteins,”
  67. (2007). Single nucleotide polymorphism associated with mature miR-125a alters the processing of primiRNA,”
  68. (2008). Suppression of non-small cell lung tumor development by the let-7 microRNA family,”
  69. (2011). The association of microRNA expression with prognosis and progression in early-stage, non-small cell lung adenocarcinoma: a retrospectiveanalysisofthreecohorts,”ClinicalCancerResearch,vol.17,
  70. (2008). The let-7 microRNA reduces tumor growth in mouse models of lung cancer,”
  71. (2010). The promise of microRNA replacement therapy,”
  72. (2007). The tumor suppressor microRNA
  73. (2011). Tumor-targeted RNAinterference: functional non-viral nanovectors,”
  74. (2006). Unique microRNA molecular profiles in lung cancer diagnosis and prognosis,”
  75. (2004). Yanagisawa et al., “Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival,”